Clostridioides difficile (C. difficile), as the major pathogen of diarrhea in healthcare settings, has become increasingly prevalent within community populations, resulting in significant morbidity and mortality. However, the therapeutic options for Clostridioides difficile infe …

Infections caused by Gram-negative pathogens are increasingly prevalent and are typically treated with broad-spectrum antibiotics, resulting in disruption of the gut microbiome and susceptibility to secondary infections1-3. There is a critical need for antibiotics that are selective both …

The antibiotic was effective against more than 130 multidrug-resistant bacterial strains

Clostridioides difficile has emerged as a major cause of life-threatening diarrheal disease. Conventional antibiotics used in current standards of care exacerbate the emergence of antibiotic-resistant strains and pose a risk of recurrent C. difficile infection (CDI). Thus, there is an urgent need fo …

Previous research has suggested that common antibiotics can disturb the gut microbiome.

Study offers proof-of-concept for developing antibiotics that can kill pathogenic Gram-negative bacteria while sparing beneficial species in the gut

Las Vegas Nevada United States As per DelveInsight s assessment globally Clostridium Difficile Infections pipeline constitutes 20 key companies continuously working towards developing 22 Clostridium Difficile Infections treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration ...

Clostridioides difficile - also known as C. diff - is the leading cause of hospital-acquired diarrhoea and can be life-threatening for older patients.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 21, 2024--

Vedanta Biosciences dosed the first subject in the Phase III RESTORATiVE303 trial of VE303 for preventing recurrent C. difficile infection.

Clostridium difficile infections are the most widely recognized cause of hospital acquired infectious diarrhea. There is a critical need for...

PureTech Health (GB:PRTC) has released an update. Vedanta Biosciences, an entity founded by PureTech Health, has initiated the Phase 3 RESTORATiVE303 trial for thei...

Newly discovered iron storage “ferrosomes” inside the bacterium C. diff — the leading cause of hospital-acquired infections — are important for infection in an animal model and could offer new targets for antibacterial drugs. They also represent a rare demonstration of a membrane-bound structure inside a pathogenic bacterium, upsetting the biological dogma that bacteria do not contain organelles. 

Ulcerative colitis (UC) is characterized by chronic inflammation and ulceration of the intestinal inner lining, resulting in various symptoms. Sea buckthorn berries contain a bioactive compound known as sea buckthorn polysaccharide (SBP). However, the precise mechanisms underlying the impact of SBP …

Iron storage “spheres” inside C. difficile, the leading cause of hospital-acquired infections, could offer new targets for antibacterial drugs.

Considering productivity costs in future cost-effectiveness analyses of vaccines for C. difficile and RSV will contribute to better-informed reimbursement decisions from a societal perspective.

Despite the technologies applied to food production, microbial contamination and chemical deterioration are still matters of great concern. In order to limit these phenomena, new natural approaches should be applied. In this context, the present study aimed to assess the antioxidant and anti-Clostri …

Interactions of bacteria with their viruses named bacteriophages or phages shape the bacterial genome evolution and contribute to the diversity of phages. RNAs have emerged as key components of several anti-phage defense systems in bacteria including CRISPR-Cas, toxin-antitoxin and abortive infectio …

Nature Communications - The Clostridium difficile virulence factors TcdA and TcdB contain a glucosyltransferase domain (GTD), which has both glucohydrolase (GH) and glucosyltransferase (GT)...

Due to envelope differences between Gram-positive and Gram-negative bacteria 1 , engineering precision bactericidal contractile nanomachines 2 requires atomic-level understanding of their structures; however, only those killing a Gram-negative bacterium are currently known …

Five host-defense peptides (figainin 2PL, hylin PL, raniseptin PL, plasticin PL, and peptide YL) were isolated from norepinephrine-stimulated skin secretions of the banana tree dwelling frog Boana platanera (Hylidae; Hylinae) collected in Trinidad. Raniseptin PL (GVFDTVKKIGKAVGKFALGVAKNYLNS.NH2 …

Clostridioides difficile infection (CDI) is a significant concern caused by widespread antibiotic use, resulting in diarrhea and inflammation from the gram-positive anaerobic bacterium C. difficile. Although bezlotoxumab (Bez), a monoclonal antibody (mAb), was developed to address CDI …

Polyphenols have shown great potential to prevent ulcerative colitis. As a natural plant polyphenol, chicoric acid (CA) has antioxidant and anti-inflammatory properties. This study explored the intervention effects and potential mechanism of CA on dextran sodium sulfate (DSS)-induced colitis mice. T …

Successful phase 2 trial leads to phase 3 trial towards managing C difficile.

Nature Communications - Chondroitin sulfate proteoglycan 4 (CSPG4) is a potential receptor for C. difficile toxin B (TcdB) during C. difficile infections (CDIs). Here, the cryo-EM structure of a...

SER-109 (VOWST™; fecal microbiota spores, live-brpk) is a live biotherapeutic product indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in patients 18 years of age and older following standard of care (SOC) antibacterial treatment for recurrent CDI. It is a p …

DelveInsight s Clostridium Difficile Infections Patient Pool Analysis Market Size and Market Forecast APAC 2034 report provides comprehensive insights into the historical and projected patient burden treatable patient population and notable market trends across the APAC region India China South ...

Acurx is a promising antibiotic company with perfect Phase 2a data in treating C. difficile infection. Find out why ACXP stock is a Buy.

Thuricin CD is a two-peptide antimicrobial produced by Bacillus thuringiensis. Unlike previous antibiotics, it has shown narrow spectrum activity against Clostridioides difficile, a bacterium capable of causing infectious disease in the colon. However, peptide antibiotics have stability, solubility, …